KCT0008214进行中（未招募）未知
Phase 1 study to evaluate the safety and the pharmacokinetics of UI061 and UIC202006 in healthy adult volunteers under fed state conditions
Korea United Pharm0 个研究点目标入组 44 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Those aged 19 years or older at the time of screening visit
- •2) Subjects with a weight of 50 kg or more (45 kg or more for women) and a body mass index (BMI) of 18.0 kg/m2 or more and 30.0 kg/m2 or less at the screening visit
- •? BMI (kg/m2) = weight (kg)/{height (m)}2
- •3) Those who have no clinically significant congenital or chronic diseases at the screening visit and no pathological symptoms or findings as a result of internal medical examination
- •4) Diagnosis tests such as hematology test, blood chemistry test, serum test, urine test, etc. and electrocardiogram test, which are set and conducted by the trial director (or the commissioned study doctor) according to the characteristics of the investigational product, and are determined to be suitable as test subjects ruler
- •5) From the first dose of investigational product to 7 days after the last dose of investigational product who agreed to
- •* Methods of contraception accepted in clinical trials: Combination of intrauterine device, vasectomy, tubal ligation and blocking contraception (male condom, female condom, cervical cap, diaphragm, sponge, etc.) Use of multiple barrier methods of contraception
- •Contraception Not Accepted in Clinical Trials: Hormonal Use
- •6) A person who voluntarily signed the consent form after receiving and understanding sufficient explanations about the purpose and contents of this clinical trial, the characteristics of the investigational product, and expected adverse reactions, etc.
排除标准
- •1) Clinically significant for digestive system, cardiovascular system, endocrine system, respiratory system, blood/oncology, infectious disease, kidney and genitourinary system, mental/nervous system, musculoskeletal system, immune system, otolaryngology, skin system, and ophthalmology system Those who have or have a history of a disease
- •2) Those with a history of gastrointestinal surgery (except for simple appendectomy or hernia surgery) that may affect drug absorption or gastrointestinal disease
- •3) Those who have taken drugs that induce or inhibit drug metabolizing enzymes such as barbiturates within 1 month of the first administration date, or who have taken drugs that may interfere with this clinical trial within 10 days of the first administration date (except for investigational drugs) Participation possible considering pharmacokinetic and pharmacodynamic characteristics such as interaction with and half-life)
- •4) Those who have administered investigational drugs by participating in other clinical trials or bioequivalence studies within 6 months of the first administration date
- •5) Whole blood donation within 8 weeks of the first administration day, component blood donation within 2 weeks, or blood transfusion within 4 weeks
- •6) Those who meet the following conditions within 1 month of the first administration date
- •For men, average alcohol consumption exceeding 21 drinks/week
- •For women, average alcohol consumption exceeding 14 drinks/week
- •(1 glass = Soju 50mL or Western liquor 30mL or Beer 250mL)
- •Smoking more than 20 cigarettes per day on average
- •7) Those who fall under the following
- •Patients with hypersensitivity to this drug or the ingredients contained in this drug
- •Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •8) Patients with the following diseases
- •Patients with severe hepatic impairment (e.g. patients with biliary cirrhosis, active liver disease, or persistent elevation of transaminase of unknown cause (more than 3 times the upper limit of normal))
- •· Patients with moderate to severe renal impairment (eGFR < 60 ml/min/1.73m2)
- •Patients who have photoallergic or phototoxic reactions during treatment with fibrates or ketoprofen
- •· Patients with gallbladder disease
- •Patients with acute or chronic pancreatitis due to hypertriglyceridemia
- •Patients with myopathy, patients with a history of rhabdomyolysis or myopathy due to statins or fibrates, and patients whose CPK level has increased more than 5 times the upper limit of normal during previous statin-based drug treatment
- •· Patients with interstitial lung disease
- •Patients with a history of pulmonary embolism
- •9) A person who is judged unsuitable for participation in this clinical trial by the trial director (or the entrusted trial physician) for reasons other than the above selection/exclusion criteria
- •10) For female volunteers, those who are pregnant or suspected of being pregnant or are breastfeeding
研究者
相似试验
尚未招募
不适用
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid TumoursNL-OMON51802DeuterOncology NV15
已完成
不适用
Phase 1 study to evaluate safety and pharmacokinetic property of DNP001 in patients with JL1 postive acute leukemia or myelodysplastic syndromeKCT0002421Asan Medical Center18
未知
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients with Advanced or Refractory Solid Tumors or LymphomaJPRN-jRCT2080223021Janssen Pharmaceutical K.K.33
已完成
1 期
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid TumorsAdvanced Solid TumorsJPRN-jRCT2080223391AstraZeneca6
进行中（未招募）
不适用
A study to evaluate the safety of panitumumab and children with solid tumoursEUCTR2014-005190-36-Outside-EU/EEAAmgen Inc36